Cited by 562Cytokine Signaling Pathways and InteractionsLung Cancer Treatments and MutationsMelanoma and MAPK Pathways

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

Open access

Lee, Ho-June, Zhuang, Guanglei, Cao, Yi, Du, Pan, Kim, Hyo-Jin, Settleman, Jeff·2014·Cancer Cell

DOI 10.1016/j.ccr.2014.05.019

Open this paper in CoChat — free account Open PDF

Abstract

Pathway-targeted cancer drugs can produce dramatic responses that are invariably limited by the emergence of drug-resistant cells. We found that many drug-treated "oncogene-addicted" cancer cells engage a positive feedback loop leading to Stat3 activation, consequently promoting cell survival and limiting overall drug response. This was observed in cancer cells driven by diverse activated kinases, including EGFR, HER2, ALK, and MET, as well as mutant KRAS. Specifically, MEK inhibition led to autocrine activation of Stat3 via the FGF receptor and JAK kinases, and pharmacological inhibition of MEK together with JAK and FGFR enhanced tumor regression. These findings suggest that inhibition of a Stat3 feedback loop may augment the response to a broad spectrum of drugs that target pathways of oncogene addiction.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2014.05.019

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,363
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Self-citation
Stat3 as an Oncogene
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Self-citation

Flagged first, then by citations

Show all 40 references

1 of the 40 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 562

Convergent Evolution, Evolving Evolvability, and the Origins of Lethal Cancer
Pienta, K. J., Hammarlund, E. U., Axelrod, R., Amend, S. R., & Brown, J. S. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1158 · Cited by 84
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
Blaquier, J. B., Ortiz‐Cuaran, S., Ricciuti, B., Mezquita, L., Cardona, A. F., & Recondo, G. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1912 · Cited by 82
Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)
Xie, S., Sun, Y., Liu, Y., Li, X., Li, X., Zhong, W., Zhan, F., Zhu, J., Yao, H., Yang, D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00270 · Cited by 81
1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities
Fathi, M. A. A., El‐Hafeez, A. A. A., Abdelhamid, D. S., Abbas, S. H., Montano, M. M., & Abdel‐Aziz, M. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.11.032 · Cited by 80
Silibinin is a direct inhibitor of STAT3
Verdura, S., Cuyàs, E., Llorach-Parés, L., Pérez-Sánchez, A., Micol, V., Nonell‐Canals, A., Joven, J., Valiente, M., Sánchez-Martínez, M., Bosch‐Barrera, J., et al. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.04.028 · Cited by 79
Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
Huang, W., Chen, L., Kang, L., Jin, M., Sun, P., Xin, X., Gao, Z., & Bae, Y. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.004 · Cited by 77
Lnc RNA SNHG20 participated in proliferation, invasion, and migration of breast cancer cells via miR‐495
Guan, Y., Zhang, M., Chen, X., Zhang, Q., Liu, S., & Zhang, Y. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26588 · Cited by 77
Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner
Ogony, J. W., Choi, H. J., Lui, A. J., Cristofanilli, M., & Lewis-Wambi, J. S. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0683-7 · Cited by 77
KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
Xie, M., Xu, X., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672612 · Cited by 80
Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities
Parakh, S., Ernst, M., & Poh, A. R. (2021) · Cancers · doi:10.3390/cancers13246228 · Cited by 77
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
Kitajima, S., Asahina, H., Chen, T., Guo, S., Quiceno, L. G., Cavanaugh, J. D., Merlino, A. A., Tange, S., Terai, H., Kim, J. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.009 · Cited by 75
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming
Adelaiye-Ogala, R. M., Budka, J. A., Damayanti, N. P., Arrington, J. V., Ferris, M. W., Hsu, C.-C., Chintala, S., Orillion, A. R., Miles, K. M., Shen, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0899 · Cited by 78
Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges
Nie, Z., Chen, M., Gao, Y., Huang, D., Cao, H., Peng, Y., Guo, N., Wang, F., & Zhang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.879317 · Cited by 83
The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers
Kozlova, N., Grossman, J. E., Iwanicki, M. P., & Muranen, T. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.01.001 · Cited by 73
Feedback regulation in cell signalling: Lessons for cancer therapeutics
Nguyen, L. K., & Kholodenko, B. Ν. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.024 · Cited by 76
Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death
Busker, S., Qian, W., Haraldsson, M., Espinosa, B., Johansson, L., Attarha, S., Kolosenko, I., Liu, J., Dagnell, M., Grandér, D., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax7945 · Cited by 74
Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivityPreprint
Zanca, C., Villa, G. R., Benítez, J. A., Thorne, A. H., Koga, T., D’Antonio, M., Ikegami, S., Ma, J., Boyer, A. D., Banisadr, A., et al. (2017) · Genes & Development · doi:10.1101/gad.300079.117 · Cited by 73
Adaptive stress signaling in targeted cancer therapy resistance
Pazarentzos, E., & Bivona, T. G. (2015) · Oncogene · doi:10.1038/onc.2015.26 · Cited by 73
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS -Mutant Non–Small Cell Lung Cancer
Araujo, H. A., Pechuan-Jorge, X., Zhou, T., Do, M. T., Hu, X., Rojas Alvarez, F. R., Salvatierra, M. E., Ibarguen, H. P., Lee, R., Raghulan, R., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0421 · Cited by 70
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis
Sharma, T., Gupta, A., Chauhan, R., Bhat, A. A., Nisar, S., Hashem, S., Akhtar, S., Ahmad, A., Haris, M., Singh, M., et al. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10026-6 · Cited by 71
HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF -Mutant Colorectal Cancer by Downregulation of c-FLIPL
Carson, R., Çeltikçi, B., Fenning, C., Javadi, A., Crawford, N., Pérez–Carbonell, L., Lawler, M., Longley, D. B., Johnston, P. G., & Schaeybroeck, S. V. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2701 · Cited by 71
Targeting novel signaling pathways for resistant acute myeloid leukemia
Sakamoto, K. M., Grant, S., Saleiro, D., Crispino, J. D., Hijiya, N., Giles, F. J., Platanias, L. C., & Eklund, E. A. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.11.017 · Cited by 69
Interleukin-6 serves as a critical factor in various cancer progression and therapy
Mohamed, A. H., Ahmed, A. T., Abdulmonem, W. A., Bokov, D. O., Shafie, A., Al‐Hetty, H. R. A. K., Hsu, C., Alissa, M., Nazir, S., Jamali, M. C., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02422-5 · Cited by 74
Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells
Jafari, R., Zolbanin, N. M., Majidi, J., Atyabi, F., Yousefi, M., Jadidi‐Niaragh, F., Maleki, L. A., Shanehbandi, D., Soltani‐Zangbar, M. S., & Rafatpanah, H. (2018) · Iranian Biomedical Journal · doi:10.29252/ibj.23.1.21 · Cited by 68
Genetics and Biology of Pancreatic Ductal Adenocarcinoma
Dunne, R. F., & Hezel, A. F. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.04.003 · Cited by 68
Targeting the Mitochondrial Metabolic Network: A Promising Strategy in Cancer Treatment
Frattaruolo, L., Brindisi, M., Curcio, R., Marra, F., Dolce, V., & Cappello, A. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176014 · Cited by 66
Optimizing lung cancer treatment approaches
Rosell, R., & Karachaliou, N. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.225 · Cited by 66
STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer
Cuyàs, E., Pérez-Sánchez, A., Micol, V., Menéndez, J. A., & Bosch‐Barrera, J. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1245249 · Cited by 65
Role of STAT3 signaling transduction pathways in cancer stem cell-associated chemoresistance
Shih, P., & Mei, K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.11.032 · Cited by 62
CCL2-SQSTM1 positive feedback loop suppresses autophagy to promote chemoresistance in gastric cancer
Xu, W., Wei, Q., Han, M., Zhou, B., Wang, H., Zhang, J., Wang, Q., Sun, J., Feng, L., Wang, S., et al. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.25349 · Cited by 64
IL-6 promotes nuclear translocation of HIF-1α to aggravate chemoresistance of ovarian cancer cells
Xu, S., Yu, C., Ma, X., Li, Y., Shen, Y., Chen, Y., Huang, S., Zhang, T., Deng, W., & Wang, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173817 · Cited by 61
Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects
Qureshi, R., Zou, B., Alam, T., Wu, J., Lee, V. H.-F., & Yan, H. (2022) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2022.3141697 · Cited by 61
Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling
Zheng, H., Yang, L., Kang, Y., Chen, M., Lin, S., Xiang, Y., Li, C., Dai, X., Huang, X., Liang, G., et al. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22951 · Cited by 61
STAT3 and p53: Dual Target for Cancer Therapy
Pham, T., Park, H., Kim, J., Hong, J. T., & Yoon, D. (2020) · Biomedicines · doi:10.3390/biomedicines8120637 · Cited by 63
Circular RNA circVAPA promotes chemotherapy drug resistance in gastric cancer progression by regulating miR-125b-5p/STAT3 axis
Deng, P., Sun, M., Zhao, W., Hou, B., Li, K., Zhang, T., & Gu, F. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i6.487 · Cited by 60
Modeling of signaling crosstalk-mediated drug resistance and its implications on drug combination
Sun, X., Bao, J., You, Z., Chen, X., & Cui, J. (2016) · Oncotarget · doi:10.18632/oncotarget.11745 · Cited by 59
RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1 -Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
Bockorny, B., Rusan, M., Chen, W., Liao, R. G., Li, Y. Y., Piccioni, F., Wang, J., Tan, L., Thorner, A. R., Li, T., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0464 · Cited by 61
HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
Yang, H., Liang, S.-Q., Xu, D., Yang, Z., Marti, T. M., Gao, Y., Kocher, G. J., Zhao, H., Schmid, R. A., & Peng, R.-W. (2019) · Oncogenesis · doi:10.1038/s41389-019-0158-7 · Cited by 58
Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas
Sun, X., Liu, X., Xia, M., Shao, Y., & Zhang, X. D. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1908-1 · Cited by 58
A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib
Yu, H. A., Perez, L., Chang, Q., Gao, S. P., Kris, M. G., Riely, G. J., & Bromberg, J. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.140 · Cited by 58
STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics
Zulkifli, A., Tan, F. H., Putoczki, T. L., Stylli, S. S., & Luwor, R. B. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.010 · Cited by 59
Tanshinone I inhibits the growth and metastasis of osteosarcoma via suppressing JAK/STAT3 signalling pathway
Wang, W., Li, J., Ding, Z., Li, Y., Wang, J., Chen, S., & Miao, J. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14539 · Cited by 57
Magnolin promotes autophagy and cell cycle arrest via blocking LIF/Stat3/Mcl-1 axis in human colorectal cancers
Yu, H., Yin, S., Zhou, S., Shao, Y., Sun, J., Pang, X., Han, L., Zhang, Y., Gao, X., Jin, C., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0660-4 · Cited by 56
FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition
Brown, W. S., Akhand, S. S., & Wendt, M. K. (2016) · Oncotarget · doi:10.18632/oncotarget.13117 · Cited by 56
Lusianthridin targeting of lung cancer stem cells via Src-STAT3 suppression
Bhummaphan, N., Petpiroon, N., Prakhongcheep, O., Sritularak, B., & Pithi Chanvorachote, B. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152932 · Cited by 55
Multi-omics profiling reveals key signaling pathways in ovarian cancer controlled by STAT3
Lu, T., Bankhead, A., Ljungman, M. E., & Neamati, N. (2019) · Theranostics · doi:10.7150/thno.33444 · Cited by 55
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
Wang, V. E. H., Xue, J. Y., Frederick, D. T., Cao, Y., Lin, E., Wilson, C., Urisman, A., Carbone, D. P., Flaherty, K. T., Bernards, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2779 · Cited by 57
Self-citation
STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy
Yang, P.-L., Liu, L.-X., Li, E., & Xu, L. (2020) · Cancers · doi:10.3390/cancers12092459 · Cited by 57
Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells
Wang, J., Lv, X., Guo, X., Dong, Y., Peng, P., Huang, F., Wang, P., Zhang, H. M., Zhou, J., Wang, Y., et al. (2021) · Oncogenesis · doi:10.1038/s41389-020-00292-w · Cited by 57
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
Peng, D. H., Kundu, S. T., Fradette, J. J., Diao, L., Tong, P., Byers, L. A., Wang, J., Canales, J. R., Villalobos, P. A., Mino, B., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1238 · Cited by 53
Edible and cation-free kiwi fruit derived vesicles mediated EGFR-targeted siRNA delivery to inhibit multidrug resistant lung cancer
Huang, H., Yi, X., Wei, Q., Li, M., Cai, X., Lv, Y., Weng, L., Mao, Y., Fan, W., Zhao, M., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01766-w · Cited by 53
Overview on the Role of E-Cadherin in Gastric Cancer: Dysregulation and Clinical Implications
Zhao, H., Hu, H., Chen, B., Xu, W., Zhao, J., Huang, C. K., Xing, Y., Lv, H., Nie, C., Wang, J., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.689139 · Cited by 54
Degraders upgraded: the rise of PROTACs in hematological malignancies
Casan, J. M. L., & Seymour, J. F. (2024) · Blood · doi:10.1182/blood.2023022993 · Cited by 53
Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3
Shou, J., You, L., Yao, J., Xie, J., Jing, J., Zhao, J., Jiang, L., Sui, X., Pan, H., & Han, W. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.002 · Cited by 52
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors
Gelfo, V., Rodia, M. T., Pucci, M., Dall’Ora, M., Santi, S., Solmi, R., Roth, L. E., Lindzen, M., Bonafè, M., Bertotti, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12354 · Cited by 53
Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway
Yang, L., Li, J., Xu, L., Lin, S., Xiang, Y., Dai, X., Liang, G., Huang, X., Zhu, J., & Zhao, C. (2019) · Cancer Management and Research · doi:10.2147/cmar.s171517 · Cited by 52
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
Bousquet, E., Bernardo, S., Papon, L., Mancini, M., Fabbrizio, E., Goussard, M., Ferrer, I., Giry, A., Quantin, X., Pujol, J.-L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126896 · Cited by 52
Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer
Wang, X., Jiang, W., Du, Y., Dongqi, Z., Zhang, J., Fang, C., Fang, Y., & Chen, Z.-S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100884 · Cited by 53
Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells
Zhao, C., Xiao, H., Wu, X., Li, C., Liang, G., Yang, S., & Lin, J. (2015) · Oncotarget · doi:10.18632/oncotarget.3991 · Cited by 51
The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer
Canesin, G., Axelsson, S. E., Hellsten, R., Sterner, O., Krzyzanowska, A., Andersson, T., & Bjartell, A. S. (2015) · European Urology · doi:10.1016/j.eururo.2015.06.016 · Cited by 51
Epigenetic regulators of programmed death-ligand 1 expression in human cancers
Kumar, S., & Sharawat, S. K. (2018) · Translational research · doi:10.1016/j.trsl.2018.05.011 · Cited by 55
Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)
Codony, C., Codony‐Servat, J., Karachaliou, N., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Ramírez, J. L., Gil, M. D. L. L., Solca, F., Bivona, T. G., & Rosell, R. (2017) · Oncotarget · doi:10.18632/oncotarget.17625 · Cited by 50
Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance
Hashimoto, S., Hashimoto, A., Muromoto, R., Kitai, Y., Oritani, K., & Matsuda, T. (2022) · Cells · doi:10.3390/cells11162618 · Cited by 51
Chronic Myeloid Leukemia: Advances in Understanding Disease Biology and Mechanisms of Resistance to Tyrosine Kinase Inhibitors
Eide, C. A., & O’Hare, T. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0248-3 · Cited by 52
Impedimetric quantification of the formation process and the chemosensitivity of cancer cell colonies suspended in 3D environment
Lei, K. F., Wu, Z.-M., & Huang, C. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.07.060 · Cited by 50
A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects
Lee, H. J., Min, H.-Y., Yong, Y.-S., Ann, J., Nguyen, C.-T., La, M. T., Hyun, S. Y., Le, H. T., Kim, H., Kwon, H.-J., et al. (2021) · Theranostics · doi:10.7150/thno.63788 · Cited by 49
Self-citation
Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling
Xiao, J.-F., Caliri, A. W., Duex, J. E., & Theodorescu, D. (2021) · Cancers · doi:10.3390/cancers13194891 · Cited by 48
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer
Santoni, M., Massari, F., Re, M. D., Ciccarese, C., Piva, F., Principato, G., Montironi, R., Santini, D., Danesi, R., Tortora, G., et al. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1020370 · Cited by 49
ZIC5 Drives Melanoma Aggressiveness by PDGFD-Mediated Activation of FAK and STAT3
Satow, R., Nakamura, T., Kato, C., Endo, M., Tamura, M., Batori, R., Tomura, S., Murayama, Y., & Fukami, K. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0991 · Cited by 48
Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer
Han, E. S., Wen, W. X., Dellinger, T. H., Wu, J., Lu, S. A., Jove, R., & Yim, J. H. (2018) · Oncotarget · doi:10.18632/oncotarget.24368 · Cited by 51
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer
Yoshida, R., Saigí, M., Tani, T., Springer, B. F., Shibata, H., Kitajima, S., Mahadevan, N. R., Campisi, M., Kim, W., Kobayashi, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0770 · Cited by 47
Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia
Fang, K., Sun, M., Leng, Z., Chu, Y., Zhao, Z., Li, Z., Zhang, Y., Xu, A., Zhang, Z., Zhang, L., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02623-2 · Cited by 49
Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway
Ma, P., Fu, Y., Chen, M., Jing, Y., Wu, J., Li, K., Shen, Y. H., Gao, J., Wang, M., Zhao, X., et al. (2016) · Theranostics · doi:10.7150/thno.14409 · Cited by 48
Self-citation
Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides
Aubry, A., Galiacy, S. D., & Allouche, M. (2019) · Cancers · doi:10.3390/cancers11030275 · Cited by 47
Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase
Orlando, E., Aebersold, D. M., Medová, M., & Zimmer, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.12.001 · Cited by 46
Tumor‐associated macrophage‐derived CCL5 promotes chemotherapy resistance and metastasis in prostatic cancer
Ma, J., Shayiti, F., Ma, J., Meng, W., Hua, T., Zhang, R., Su, J., & Chen, P. (2021) · Cell Biology International · doi:10.1002/cbin.11630 · Cited by 46
ALK in cancer: from function to therapeutic targeting
Voena, C., Ambrogio, C., Iannelli, F., & Chiarle, R. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00797-9 · Cited by 49
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
Ku, B. M., Bae, Y. H., Lee, K. Y., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00795-3 · Cited by 45
Autocrine IL-6/STAT3 signaling aids development of acquired drug resistance in Group 3 medulloblastoma
Sreenivasan, L., Wang, H., Yap, S. Q., Leclair, P., Tam, A., & Lim, C. J. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03241-y · Cited by 48
Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
Phan, A. N. H., Hua, T. N. M., Kim, M.-K., Vo, V. T. A., Choi, J.-W., Kim, H.-W., Rho, J. K., Kim, K. W., & Jeong, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.10581 · Cited by 44
Self-citation
Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC
Jiang, L., Guo, F., Liu, X., Li, X., Qin, Q., Shu, P., Li, Y., & Wang, Y. (2019) · Scientific Reports · doi:10.1038/s41598-018-38068-3 · Cited by 44
Brevilin A induces ROS-dependent apoptosis and suppresses STAT3 activation by direct binding in human lung cancer cells
Khan, M. N., Maryam, A., Saleem, M. Z., Shakir, H. A., Qazi, J. I., Li, Y., & Ma, T. (2020) · Journal of Cancer · doi:10.7150/jca.40983 · Cited by 43
Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy
Zhao, Y., Wang, H., & He, C. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03828-8 · Cited by 45
STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell
Bu, L., Zhao, Z., Liu, J., Ma, S., Huang, C., Liu, B., Zhang, W., & Sun, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.5986 · Cited by 42
Multidrug Delivery Systems Based on Human Serum Albumin for Combination Therapy with Three Anticancer Agents
Qi, J., Zhang, Y., Gou, Y., Lee, P., Wang, J., Chen, S., Zhou, Z., Wu, X., Yang, F., & Liang, H. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00277 · Cited by 42
Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer
Cai, X., Jing, M., Sun, R., Wang, S., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Rosell, R., & Cao, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105701 · Cited by 41
CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity
Vallath, S., Sage, E. K., Kolluri, K. K., Lourenco, S. D. S., TEIXEIRA, V. H., Chimalapati, S., George, P. J., Janes, S. M., & Giangreco, A. (2016) · Scientific Reports · doi:10.1038/srep24006 · Cited by 41
Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation
Aldonza, M. B. D., Hong, J., Alinsug, M. V., Song, J., & Lee, S. K. (2016) · Oncotarget · doi:10.18632/oncotarget.9118 · Cited by 42
The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism
Calvayrac, O., Mazières, J., Figarol, S., Marty‐Detraves, C., Raymond‐Letron, I., Bousquet, E., Farella, M., Clermont, E., Milia, J., Rouquette, I., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606646 · Cited by 41
Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation
Aldonza, M. B. D., Hong, J., & Lee, S. K. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.131 · Cited by 42
JAK2 variations and functions in lung adenocarcinoma
Xu, Y., Jin, J. F., Xu, J., Shao, Y. W., & Fan, Y. (2017) · Tumor Biology · doi:10.1177/1010428317711140 · Cited by 41
STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non–Small Cell Lung Cancer
Njatcha, C., Farooqui, M., Kornberg, A. E., Johnson, D. E., Grandis, J. R., & Siegfried, J. M. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1194 · Cited by 41
Multifunctional Gold Nanoparticles Overcome MicroRNA Regulatory Network Mediated-Multidrug Resistant Leukemia
Deng, R., Ji, B., Yu, H., Bao, W., Yang, Z., Yu, Y. F., Cui, Y., Du, Y., Song, M., Liu, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41866-y · Cited by 41
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression
Napolitano, S., Matrone, N., Muddassir, A. L., Martini, G., Sorokin, A., De Falco, V., Giunta, E. F., Ciardiello, D., Martinelli, E., Belli, V., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1497-0 · Cited by 40
Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
Mumin, N. H., Drobnitzky, N., Patel, A., Lourenço, L. M., Cahill, F. F., Jiang, Y., Kong, A. H., & Ryan, A. J. (2019) · BMC Cancer · doi:10.1186/s12885-019-5295-z · Cited by 40
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
Liao, B.-C., Griesing, S., & Yang, J. C. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919890286 · Cited by 40
Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer
Abdullah, A., Akhand, S. S., Paez, S. J., Brown, W. S., Li, P., Libring, S., Badamy, M., Dykhuizen, E. C., Solorio, L., Tao, W. A., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01530-6 · Cited by 40
Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy
Swayden, M., Chhouri, H., Anouar, Y., & Grumolato, L. (2020) · Cells · doi:10.3390/cells9122601 · Cited by 47
Targeting Stem Cells and Dysplastic Features With Dual MEK/ERK and STAT3 Suppression in Gastric Carcinogenesis
Kim, H., Jang, B. G., Zhang, C., Caldwell, B. M., Park, D. J., Kong, S., Lee, H.-J., Yang, H., Goldenring, J. R., & Choi, E.-Y. K. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.09.040 · Cited by 40
Self-citation
Overexpression of Bcl-2 induces STAT-3 activation via an increase in mitochondrial superoxide
Kang, J., Chong, S. J. F., Ooi, V. Z. Q., Vali, S., Kumar, A., Kapoor, S., Abbasi, T., Hirpara, J. L., Loh, T. K. S., Goh, B. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5763 · Cited by 39

Authors: Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J.
Affiliations: Genentech (US)
Corresponding author: Settleman, Jeff
ORCID: Lee, Ho-June
Zhuang, Guanglei
Cao, Yi
Du, Pan
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2014-08
Volume: 26
Issue: 2
Pages: 207-221
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2014.05.019
OpenAlex: W2102365935
Cited by: 555
References: 40
Citations by year: 2026: 23 · 2025: 27 · 2024: 36 · 2023: 41 · 2022: 38 · 2021: 61 · 2020: 55 · 2019: 63 · 2018: 46 · 2017: 65 · 2016: 54 · 2015: 42 · 2014: 4
FWCI: 26.52
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 375 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords: STAT3, drug resistance, oncogene addiction, positive feedback loop, MEK inhibition, JAK inhibition, fibroblast growth factor receptor, EGFR, HER2, anaplastic lymphoma kinase, MET, mutant KRAS, autocrine signaling, combination therapy, tumor regression
MeSH terms: Erlotinib Hydrochloride, Adenocarcinoma of Lung, Adenocarcinoma, Animals, Antineoplastic Agents, Cell Survival, Humans, Imidazoles, Lung Neoplasms, Mutation, Nitriles, Oncogenes, Proto-Oncogene Proteins, Pyrazoles, Pyridazines, Pyrimidines, Quinazolines, Signal Transduction, Interleukin-6, Proto-Oncogene Proteins p21(ras), Mice, SCID, Receptors, Fibroblast Growth Factor, ras Proteins, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, STAT3 Transcription Factor, Mice, Kaplan-Meier Estimate, Janus Kinase 1, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks